567 related articles for article (PubMed ID: 24965506)
21. Statistical Effects of Religious Participation and Marriage on Substance Use and Abuse in Racial and Ethnic Minorities.
Hearld KR; Badham A; Budhwani H
J Relig Health; 2017 Aug; 56(4):1155-1169. PubMed ID: 27900640
[TBL] [Abstract][Full Text] [Related]
22. Racial/Ethnic composition of study participants in FDA-approved oncology new molecular entities, 2006-2008.
Merenda C
J Natl Med Assoc; 2012; 104(9-10):430-5. PubMed ID: 23342816
[TBL] [Abstract][Full Text] [Related]
23. Demographic Composition of Select Oncologic New Molecular Entities Approved by the FDA Between 2008 and 2017.
Ramamoorthy A; Knepper TC; Merenda C; Mendoza M; McLeod HL; Bull J; Zhang L; Pacanowski M
Clin Pharmacol Ther; 2018 Nov; 104(5):940-948. PubMed ID: 30218447
[TBL] [Abstract][Full Text] [Related]
24. Mind the gap: efficacy versus effectiveness and pivotal prostate cancer clinical trial demographics.
Galsky MD; Oh WK
Cancer; 2014 Oct; 120(19):2944-5. PubMed ID: 24965362
[No Abstract] [Full Text] [Related]
25. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
26. Racial/Ethnic Disparities in Ophthalmology Clinical Trials Resulting in US Food and Drug Administration Drug Approvals From 2000 to 2020.
Berkowitz ST; Groth SL; Gangaputra S; Patel S
JAMA Ophthalmol; 2021 Jun; 139(6):629-637. PubMed ID: 33885724
[TBL] [Abstract][Full Text] [Related]
27. Characteristics of orphan drug applications that fail to achieve marketing approval in the USA.
Heemstra HE; Leufkens HG; Rodgers RP; Xu K; Voordouw BC; Braun MM
Drug Discov Today; 2011 Jan; 16(1-2):73-80. PubMed ID: 21094692
[TBL] [Abstract][Full Text] [Related]
28. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
DiMasi JA
Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
[TBL] [Abstract][Full Text] [Related]
29. Increasing accrual in cancer clinical trials with a focus on minority enrollment: The William Beaumont Hospital Community Clinical Oncology Program Experience.
Vicini F; Nancarrow-Tull J; Shah C; Chmielewski G; Fakhouri M; Sitarek SA; Feczko CT; Brzozowski C; Felten DL
Cancer; 2011 Oct; 117(20):4764-71. PubMed ID: 21455995
[TBL] [Abstract][Full Text] [Related]
30. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
[TBL] [Abstract][Full Text] [Related]
31. Does study subject diversity influence cardiology research site performance?: Insights from 2 U.S. National Coronary Stent Registries.
Batchelor WB; Damluji AA; Yong C; Fiuzat M; Barnett SD; Kandzari DE; Sherwood MW; Epps KC; Tehrani BN; Allocco DJ; Meredith IT; Lindenfeld J; O'Connor CM; Mehran R
Am Heart J; 2021 Jun; 236():37-48. PubMed ID: 33636137
[TBL] [Abstract][Full Text] [Related]
32. Overcoming Barriers: Evidence-Based Strategies to Increase Enrollment of Underrepresented Populations in Cancer Therapeutic Clinical Trials-a Narrative Review.
Vuong I; Wright J; Nolan MB; Eggen A; Bailey E; Strickland R; Traynor A; Downs T
J Cancer Educ; 2020 Oct; 35(5):841-849. PubMed ID: 31713103
[TBL] [Abstract][Full Text] [Related]
33. Diversity in Orthopaedic Surgery Medical Device Clinical Trials: An Analysis of the Food and Drug Administration Safety and Innovation Act.
Issa TZ; Lambrechts MJ; Lin JS; Brush PL; Canseco JA; Hilibrand AS; Kepler CK; Schroeder GD; Vaccaro AR
J Am Acad Orthop Surg; 2023 Feb; 31(3):155-165. PubMed ID: 36525566
[TBL] [Abstract][Full Text] [Related]
34. Racial representation in clinical trials for dermatological new molecular entities.
Ha MV; Wong C
Clin Exp Dermatol; 2022 Feb; 47(2):386-388. PubMed ID: 34346107
[TBL] [Abstract][Full Text] [Related]
35. Racial disparities among clinical research investigators.
Getz K; Faden L
Am J Ther; 2008; 15(1):3-11. PubMed ID: 18223347
[TBL] [Abstract][Full Text] [Related]
36. Enrollment of racial/ethnic minorities and women with HIV in clinical research studies of HIV medicines.
Sullivan PS; McNaghten AD; Begley E; Hutchinson A; Cargill VA
J Natl Med Assoc; 2007 Mar; 99(3):242-50. PubMed ID: 17393948
[TBL] [Abstract][Full Text] [Related]
37. Duration of Pediatric Clinical Trials Submitted to the US Food and Drug Administration.
Zimmerman KO; Smith PB; McMahon AW; Temeck J; Avant D; Murphy D; McCune S
JAMA Pediatr; 2019 Jan; 173(1):60-67. PubMed ID: 30452504
[TBL] [Abstract][Full Text] [Related]
38. A systematic review of the prevalence of herb usage among racial/ethnic minorities in the United States.
Gardiner P; Whelan J; White LF; Filippelli AC; Bharmal N; Kaptchuk TJ
J Immigr Minor Health; 2013 Aug; 15(4):817-28. PubMed ID: 22723252
[TBL] [Abstract][Full Text] [Related]
39. Reporting, representation, and subgroup analysis of race and ethnicity in published clinical trials of atopic dermatitis in the United States between 2000 and 2009.
Hirano SA; Murray SB; Harvey VM
Pediatr Dermatol; 2012; 29(6):749-55. PubMed ID: 23017105
[TBL] [Abstract][Full Text] [Related]
40. Progress in improving mental health services for racial-ethnic minority groups: a ten-year perspective.
Santiago CD; Miranda J
Psychiatr Serv; 2014 Feb; 65(2):180-5. PubMed ID: 24178249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
